Low-carbohydrate, high-fat (LCHF) nutrition therapy is characterized by carbohydrates comprising <26% of the daily caloric intake and a higher proportion of fat. LCHF therapies reduce exogenous glucose load, improve glycemic control, decrease inflammation, and improve clinical outcomes such as respiratory function. Given the altered metabolism in critically ill patients, LCHF nutrition therapy may be especially beneficial as it enables the conservation of protein and glucose for metabolic roles beyond energy use. In critical illness, LCHF diets have the potential to reduce hyperglycemia, improve ventilation, decrease hospital length of stay and reduce hospital costs. The purpose of this commentary piece is to describe LCHF nutrition therapy, summarize its impact on health outcomes, and discuss its role in the intensive care unit (ICU). Additional research on the effects of LCHF nutrition therapy on critically ill patients is warranted, including a focus on COVID-19.

Download full-text PDF

Source
http://dx.doi.org/10.1177/02601060221149088DOI Listing

Publication Analysis

Top Keywords

role low-carbohydrate
4
low-carbohydrate diets
4
diets intensive
4
intensive care
4
care unit
4
unit low-carbohydrate
4
low-carbohydrate high-fat
4
high-fat lchf
4
lchf nutrition
4
nutrition therapy
4

Similar Publications

Article Synopsis
  • This study examines a new healthcare model in New Zealand that combines a low-carbohydrate diet and health coaching to help manage prediabetes and Type 2 diabetes.
  • Participants reported health benefits like weight loss and increased energy, while also facing challenges such as resistance from some healthcare providers and misconceptions about low-carb diets.
  • The model shows promise for improving patient outcomes and reducing the workload on healthcare professionals, though further education and awareness are needed for wider adoption.
View Article and Find Full Text PDF

: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of fertile age. Some studies suggest that a ketogenic diet (KD) may have a role in treating PCOS. We aimed to demonstrate the long-term effectiveness of a KD in PCOS.

View Article and Find Full Text PDF

Diet-gut microbiome interaction and its impact on host blood glucose homeostasis: a series of nutritional n-of-1 trials.

EBioMedicine

December 2024

Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China; Zhejiang Key Laboratory of Multi-Omics in Infection and Immunity, School of Medicine and School of Life Sciences, Westlake University, Hangzhou, China; Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China. Electronic address:

Background: The interplay between diet and gut microbiome substantially influences host metabolism, but uncertainties remain regarding their relationships tailored for each subject given the huge inter-individual variability. Here we aim to investigate diet-gut microbiome interaction at single-subject resolution and explore its effects on blood glucose homeostasis.

Methods: We conducted a series of nutritional n-of-1 trials (NCT04125602), in which 30 participants were assigned high-carbohydrate (HC) and low-carbohydrate (LC) diets in a randomized sequence across 3 pair of cross-over periods lasting 72 days.

View Article and Find Full Text PDF

Background: Endothelial dysfunction (ED) is induced by insulin resistance, mediated by endoplasmic reticulum (ER) stress and disturbed autophagy. This study investigates the protective role of a low-carbohydrate, high-fat (LCHF) diet on ED, ER stress, and autophagy dysregulation in an experimental animal model of metabolic syndrome.

Methods: Forty male Sprague-Dawley rats were divided into four groups: a Control group (standard diet) and three Dexamethasone (DEX) treated groups.

View Article and Find Full Text PDF
Article Synopsis
  • Cystic fibrosis (CF) modulators have improved patient outcomes, but individual responses vary, especially regarding respiratory issues; the study explores the effects of ketone monoester (KME) on CF patients by boosting D-beta hydroxybutyrate concentrations and assessing quality of life and inflammation.
  • Fourteen adults on modulator therapy were divided into two groups: one received KME and the other a placebo for 5-7 days while hospitalized or as outpatients; KME was well tolerated, showing significant increases in D-βHB levels and better self-reported respiratory scores compared to the placebo group.
  • Although short-term KME administration didn’t significantly change plasma inflammatory markers, there were notable differences in
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!